Inhibrx Biosciences, Inc. Common Stock (INBX)

Price$87.01

Value ScoreD

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-4.49%

Price vs S&P 500 (4W)-35.23%

VGM Score50.03

Market Capitalization$1.28B

P/E Ratio (Annual)0.55x

All Metrics

Book Value / Share (Quarterly)$0.55

P/TBV (Annual)16.73x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-15.96%

Cash Flow / Share (Quarterly)$-6.72

Price vs S&P 500 (YTD)1.98%

Net Profit Margin (TTM)-5465.64%

EPS (TTM)$-6.24

10-Day Avg Trading Volume0.34M

EPS Excl Extra (TTM)$-6.24

Revenue Growth (5Y)-36.80%

EPS (Annual)$-9.04

ROI (Annual)-129.02%

Net Profit Margin (5Y Avg)162368.22%

Cash / Share (Quarterly)$11.07

P/E Normalized (Annual)0.55x

ROA (Last FY)-95.62%

Revenue Growth TTM (YoY)550.00%

EBITD / Share (TTM)$-5.79

ROE (5Y Avg)-289.95%

Operating Margin (TTM)-5522.64%

Cash Flow / Share (Annual)$-8.91

P/B Ratio159.71x

P/B Ratio (Quarterly)143.75x

Net Income / Employee (Annual)$-1,284,900

EV / Revenue (TTM)921.34x

Net Interest Coverage (TTM)-29.14x

ROA (TTM)-54.14%

EV / EBITDA (TTM)0.76x

EPS Incl Extra (Annual)$-9.04

Current Ratio (Annual)3.93x

Quick Ratio (Quarterly)6.10x

3-Month Avg Trading Volume0.35M

52-Week Price Return575.02%

Revenue / Employee (TTM)$11,900

Tangible BV / Share (Quarterly)$2.74

P/S Ratio (Annual)981.95x

Asset Turnover (Annual)0.01x

52-Week High$155.29

Operating Margin (5Y Avg)163100.94%

EPS Excl Extra (Annual)$-9.04

CapEx CAGR (5Y)-53.06%

26-Week Price Return3.44%

Quick Ratio (Annual)3.68x

13-Week Price Return23.14%

Total Debt / Equity (Annual)12.58x

Current Ratio (Quarterly)6.46x

Enterprise Value$1.29B

Revenue / Share Growth (5Y)-24.49%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-22.80%

Revenue / Employee (Annual)$11,900

Pretax Margin (Annual)-10773.31%

Cash / Share (Annual)$8.52

3-Month Return Std Dev113.92%

Net Income / Employee (TTM)$-887,600

ROE (Last FY)-1752.22%

Net Interest Coverage (Annual)-21.57x

EPS Basic Excl Extra (Annual)$-9.04

Receivables Turnover (TTM)4.96x

Total Debt / Equity (Quarterly)12.58x

EPS Incl Extra (TTM)$-6.24

Receivables Turnover (Annual)0.33x

ROI (TTM)-70.25%

P/S Ratio (TTM)911.81x

Pretax Margin (5Y Avg)162386.73%

Revenue / Share (Annual)$0.08

Tangible BV / Share (Annual)$1.33

Price vs S&P 500 (52W)550.65%

Year-to-Date Return10.14%

5-Day Price Return-12.37%

EPS Normalized (Annual)$-9.04

ROA (5Y Avg)131.06%

Net Profit Margin (Annual)-10773.46%

Month-to-Date Return-16.34%

Cash Flow / Share (TTM)$-4.22

EBITD / Share (Annual)$-8.56

Operating Margin (Annual)-10386.54%

LT Debt / Equity (Annual)12.58x

ROI (5Y Avg)183.12%

LT Debt / Equity (Quarterly)12.58x

EPS Basic Excl Extra (TTM)$-6.24

P/TBV (Quarterly)7.50x

P/B Ratio (Annual)143.75x

Pretax Margin (TTM)-5465.50%

Book Value / Share (Annual)$0.55

Price vs S&P 500 (13W)14.88%

Beta2.92x

Revenue / Share (TTM)$0.08

ROE (TTM)-255.98%

52-Week Low$12.80

vGradeD

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-2.15est. -1.82

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

2.17

4.11

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$87.01
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapies using its proprietary protein engineering platform. The company's pipeline includes INBRX-109 and INBRX-106, multivalent therapeutic candidates designed to optimize target engagement and agonist activity.